NewAmsterdam Pharma Company N.V. (NAMS)
UndervaluedFundamental
28
Price
$24.32
Market Cap
$2.91B
Part 1 · What the company is worth
Overview
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on September 19, 2026 with claude-haiku-4-5 — shared with all users
Merck's oral PCSK9 inhibitor enlicitide (Lipfendra) targets exactly the same patients obicetrapib is aimed at — people whose LDL cholesterol stays high on statins — and, like obicetrapib, it is a daily pill rather than an injection.
Amgen's Repatha (evolocumab) is the leading add-on therapy for lowering LDL cholesterol on top of statins, the same commercial slot obicetrapib is being positioned for.
Regeneron, with Sanofi, sells Praluent (alirocumab), one of the two injectable PCSK9 inhibitors NewAmsterdam's own filings name as the benchmark obicetrapib is measured against.
AstraZeneca is developing AZD0780, an oral LDL-lowering pill cited in NewAmsterdam's risk factors as a rival for the same prescriptions obicetrapib is seeking.
Esperion sells Nexletol and Nexlizet, the oral non-statin pills prescribed today to the statin-treated patients NewAmsterdam wants to reach, and the 10-K names them among the therapies obicetrapib would have to displace.
Novartis markets Leqvio (inclisiran), a twice-yearly injection sold to cardiologists and lipid clinics for the same high-risk cardiovascular patients obicetrapib would treat.
Balance Sheet & Liquidity
Revenue
$7M
Trailing 12 months (through 6/30/2026)
Net Income
$-260M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$-148M
Total Equity
$683M
Total Liabilities
$86M
Current Ratio
9.03
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$33.85
Current Price
$24.32
Margin of Safety
+28.2%
Fair Value Range
$22.00 - $45.70
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
-
ROE
-29.8%
P/B Ratio
4.60
P/FCF
-
Gross Margin
-
ROIC
-30.6%
Profitability Radar
Value Creation (Economic Moat)
ROIC
-30.6%
WACC
8.0%
ROIC − WACC
-38.6 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (6)
- EPS shows upward trend
- Price CAGR 18.40%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 91% Buy
Failed (11)
- ROIC -30.6%
- P/B Ratio 4.60
- Operating Margin -3432.2%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Overvalued)
- ROE -38.3%
- Earnings Surprise avg -23.2%
- Share Dilution 25.6%
- Net Margin Trend -3644.2% vs -258.9%
- Piotroski F-Score 3/9
Unavailable (10)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Serious financial concerns
Earnings Quality
Low quality: investigate accounting
Share Dilution
Issuing new shares, diluting ownership
Institutional Holdings
No institutional filings reported for this company.
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Dr. Michael Harvey Davidson FACC, Facp., M.D. | CEO, President & Executive Director | 69 |
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board & Director | 71 |
| Mr. Mayur Amrat Somaiya | Chief Financial Officer | 51 |
| Mr. Robert W. Gunning C.P.A., CGMA | Principal Accounting Officer, VP & Controller | 54 |
| Mr. Matthew Philippe | Executive VP & Head of Investor Relations | - |
| Mr. Michael F. Marino Esq. | Chief Legal Officer & Corporate Secretary | 49 |
| Mr. Chris Deluzio | Executive Vice President of Sales Enterprise Operations | - |
| Ms. Maryellen McQuade | Chief People Officer | - |
| Ms. Juliette Audet M.B.A., M.Sc. | Chief Strategy & Business Officer | 38 |
| Dr. Marc Ditmarsch M.D. | Chief Development Officer | 58 |
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-18
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-08-05
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-09-29
via SEC EDGAR
Income History
via SEC EDGAR
Latest News
Recent headlines for NAMS, sourced from Markets Gazette.